Effectiveness of the Early Addition of Abacavir to an Anti-HIV Drug Combination
Status:
Completed
Trial end date:
2001-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see if adding 1 drug to an anti-HIV drug combination early in
treatment against HIV can lower the viral load (amount of HIV in the blood) to a level so low
that it cannot be measured (undetectable). The drug that will be added to a treatment is
abacavir (ABC).
Many patients who take 3 anti-HIV drugs together are able to achieve very low viral loads,
for example, viral loads below 50 copies/ml. However, some patients taking only 3 drugs are
not able to achieve a viral load this low. Doctors hope that, by adding the drug ABC to a
current treatment, a viral load below 50 copies/ml can be achieved. Doctors would like to
find out if it is effective to start patients on 3 drugs and then add another drug (treatment
intensification) if the treatment is not working as well as hoped.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)